Orthometrix, Inc.
Orthometrix, Inc. (OMRX) Stock Competitors & Peer Comparison
See (OMRX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OMRX | $0.00 | +9900.00% | 4.7K | N/A | -$0.02 | N/A |
| BMXXY | $14.55 | +0.00% | 17.2B | 38.29 | $0.38 | +0.68% |
| EBOSY | $35.03 | +7.78% | 1.8B | 24.67 | $1.42 | +3.22% |
| XVIPY | $6.54 | +0.00% | 824M | N/A | N/A | N/A |
| AVNBF | $24.00 | +4.35% | 703.5M | 70.59 | $0.34 | +1.02% |
| EBRCZ | $0.55 | -7.80% | 412.5M | -4.61 | -$0.12 | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| NVNBW | $0.01 | +0.00% | 141.5K | -0.00 | -$1.95 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
| SXHHF | $0.00 | +0.00% | 38.1K | -0.01 | -$0.01 | N/A |
Stock Comparison
OMRX vs BMXXY Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, BMXXY has a market cap of 17.2B. Regarding current trading prices, OMRX is priced at $0.00, while BMXXY trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 38.29. In terms of profitability, OMRX's ROE is -0.15%, compared to BMXXY's ROE of +0.09%. Regarding short-term risk, OMRX is more volatile compared to BMXXY. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check BMXXY's competition here
OMRX vs EBOSY Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, EBOSY has a market cap of 1.8B. Regarding current trading prices, OMRX is priced at $0.00, while EBOSY trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 24.67. In terms of profitability, OMRX's ROE is -0.15%, compared to EBOSY's ROE of +0.06%. Regarding short-term risk, OMRX is more volatile compared to EBOSY. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check EBOSY's competition here
OMRX vs XVIPY Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, XVIPY has a market cap of 824M. Regarding current trading prices, OMRX is priced at $0.00, while XVIPY trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas XVIPY's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to XVIPY's ROE of +0.05%. Regarding short-term risk, OMRX is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check XVIPY's competition here
OMRX vs AVNBF Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, AVNBF has a market cap of 703.5M. Regarding current trading prices, OMRX is priced at $0.00, while AVNBF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas AVNBF's P/E ratio is 70.59. In terms of profitability, OMRX's ROE is -0.15%, compared to AVNBF's ROE of +0.05%. Regarding short-term risk, OMRX is more volatile compared to AVNBF. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check AVNBF's competition here
OMRX vs EBRCZ Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, EBRCZ has a market cap of 412.5M. Regarding current trading prices, OMRX is priced at $0.00, while EBRCZ trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -4.61. In terms of profitability, OMRX's ROE is -0.15%, compared to EBRCZ's ROE of -2.35%. Regarding short-term risk, OMRX is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check EBRCZ's competition here
OMRX vs TRXDW Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, OMRX is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to TRXDW's ROE of -1.18%. Regarding short-term risk, OMRX is more volatile compared to TRXDW. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check TRXDW's competition here
OMRX vs NVNBW Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, NVNBW has a market cap of 141.5K. Regarding current trading prices, OMRX is priced at $0.00, while NVNBW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.00. In terms of profitability, OMRX's ROE is -0.15%, compared to NVNBW's ROE of -0.61%. Regarding short-term risk, OMRX is more volatile compared to NVNBW. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check NVNBW's competition here
OMRX vs GWPC Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, OMRX is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, OMRX's ROE is -0.15%, compared to GWPC's ROE of N/A. Regarding short-term risk, OMRX is more volatile compared to GWPC. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check GWPC's competition here
OMRX vs SXHHF Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, OMRX is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, OMRX's ROE is -0.15%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, OMRX and SXHHF have similar daily volatility (196.04).Check SXHHF's competition here
OMRX vs DGCRF Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, DGCRF has a market cap of 21.5K. Regarding current trading prices, OMRX is priced at $0.00, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is 0.00. In terms of profitability, OMRX's ROE is -0.15%, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, OMRX and DGCRF have similar daily volatility (196.04).Check DGCRF's competition here
OMRX vs KKUR Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, OMRX is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to KKUR's ROE of N/A. Regarding short-term risk, OMRX is more volatile compared to KKUR. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check KKUR's competition here
OMRX vs SCIE Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, SCIE has a market cap of 4.9K. Regarding current trading prices, OMRX is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is -0.00. In terms of profitability, OMRX's ROE is -0.15%, compared to SCIE's ROE of +0.51%. Regarding short-term risk, OMRX is more volatile compared to SCIE. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check SCIE's competition here
OMRX vs IBXG Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, OMRX is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to IBXG's ROE of N/A. Regarding short-term risk, OMRX is more volatile compared to IBXG. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check IBXG's competition here
OMRX vs DMSI Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, OMRX is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, OMRX is more volatile compared to DMSI. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check DMSI's competition here
OMRX vs AAXT Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, OMRX is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, OMRX is more volatile compared to AAXT. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check AAXT's competition here
OMRX vs XCRP Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, XCRP has a market cap of 1.5K. Regarding current trading prices, OMRX is priced at $0.00, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas XCRP's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to XCRP's ROE of -3.49%. Regarding short-term risk, OMRX is more volatile compared to XCRP. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check XCRP's competition here
OMRX vs BMGP Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, OMRX is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, OMRX is more volatile compared to BMGP. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check BMGP's competition here
OMRX vs IMRSQ Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, OMRX is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, OMRX is more volatile compared to IMRSQ. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check IMRSQ's competition here
OMRX vs STBV Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, STBV has a market cap of 471. Regarding current trading prices, OMRX is priced at $0.00, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas STBV's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to STBV's ROE of -1.13%. Regarding short-term risk, OMRX is more volatile compared to STBV. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check STBV's competition here
OMRX vs OMDD Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, OMDD has a market cap of 310. Regarding current trading prices, OMRX is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, OMRX's ROE is -0.15%, compared to OMDD's ROE of N/A. Regarding short-term risk, OMRX is more volatile compared to OMDD. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check OMDD's competition here
OMRX vs QMED Comparison February 2026
OMRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OMRX stands at 4.7K. In comparison, QMED has a market cap of 17. Regarding current trading prices, OMRX is priced at $0.00, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OMRX currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, OMRX's ROE is -0.15%, compared to QMED's ROE of N/A. Regarding short-term risk, OMRX is more volatile compared to QMED. This indicates potentially higher risk in terms of short-term price fluctuations for OMRX.Check QMED's competition here